Literature DB >> 2605969

Practical problems in interim analyses, with particular regard to estimation.

S J Pocock1, M D Hughes.   

Abstract

This article considers some of the practical problems inherent in interim analyses and stopping rules for randomized clinical trials. Topics covered include group sequential designs, trials with unplanned interim analyses, estimation problems in clinical trials with planned interim analyses, and the balance between individual and collective ethics. Particular attention is paid to the fact that clinical trials that stop early are prone to exaggerate the magnitude of treatment effect. Accordingly, a Bayesian "shrinkage" method of analysis is proposed to help quantify the extent to which surprisingly large point and interval estimates of treatment difference in clinical trials that stop early should be moderated.

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Year:  1989        PMID: 2605969     DOI: 10.1016/0197-2456(89)90059-7

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  26 in total

Review 1.  Monitoring clinical trials--interim data should be publicly available.

Authors:  R J Lilford; D Braunholtz; S Edwards; A Stevens
Journal:  BMJ       Date:  2001-08-25

2.  Should sponsors and DSMBs share interim results across trials?

Authors:  Seema K Shah; Liza Dawson; Dennis O Dixon; Reidar K Lie
Journal:  J Acquir Immune Defic Syndr       Date:  2011-12-15       Impact factor: 3.731

3.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

4.  Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005.

Authors:  Edward L Korn; Boris Freidlin; Margaret Mooney
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

5.  Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research.

Authors:  Hao Wang; Gary L Rosner; Steven N Goodman
Journal:  Clin Trials       Date:  2016-06-07       Impact factor: 2.486

6.  Advance modern medicine with clinical case reports.

Authors:  Yì-Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2014-12

7.  Bayes factor design analysis: Planning for compelling evidence.

Authors:  Felix D Schönbrodt; Eric-Jan Wagenmakers
Journal:  Psychon Bull Rev       Date:  2018-02

8.  Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial.

Authors:  Guido Bertolini; Gaetano Iapichino; Danilo Radrizzani; Rebecca Facchini; Bruno Simini; Paola Bruzzone; Giancarlo Zanforlin; Gianni Tognoni
Journal:  Intensive Care Med       Date:  2003-04-09       Impact factor: 17.440

9.  Over-EXTENDing the Window for Thrombolytic Therapy in Cerebrovascular Accident: September 2019 Annals of Emergency Medicine Journal Club.

Authors:  Rory J Spiegel; John P Donnelly; Ryan P Radecki
Journal:  Ann Emerg Med       Date:  2019-09       Impact factor: 5.721

10.  Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2).

Authors:  Matthias Briel; Melanie Lane; Victor M Montori; Dirk Bassler; Paul Glasziou; German Malaga; Elie A Akl; Ignacio Ferreira-Gonzalez; Pablo Alonso-Coello; Gerard Urrutia; Regina Kunz; Carolina Ruiz Culebro; Suzana Alves da Silva; David N Flynn; Mohamed B Elamin; Brigitte Strahm; M Hassan Murad; Benjamin Djulbegovic; Neill K J Adhikari; Edward J Mills; Femida Gwadry-Sridhar; Haresh Kirpalani; Heloisa P Soares; Nisrin O Abu Elnour; John J You; Paul J Karanicolas; Heiner C Bucher; Julianna F Lampropulos; Alain J Nordmann; Karen E A Burns; Sohail M Mulla; Heike Raatz; Amit Sood; Jagdeep Kaur; Clare R Bankhead; Rebecca J Mullan; Kara A Nerenberg; Per Olav Vandvik; Fernando Coto-Yglesias; Holger Schünemann; Fabio Tuche; Pedro Paulo M Chrispim; Deborah J Cook; Kristina Lutz; Christine M Ribic; Noah Vale; Patricia J Erwin; Rafael Perera; Qi Zhou; Diane Heels-Ansdell; Tim Ramsay; Stephen D Walter; Gordon H Guyatt
Journal:  Trials       Date:  2009-07-06       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.